Navigation Links
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
Date:4/15/2008

ity and safety of GAMMAGARD in the treatment of mild to moderate stage Alzheimer's disease.

The oral presentation, "Intravenous Immunoglobulin Increases Brain Glucose Metabolism in Alzheimer Disease," will also be presented on April 17 and will discuss the analysis of brain activity using imaging data. The brain metabolism results were based on serial Positron Emission Tomography (PET) scans, an imaging technique sometimes used in the diagnosis of Alzheimer's disease.

Further, Baxter and The Alzheimer's Disease Cooperative Study (ADCS) group announced a decision to pursue a multi-center U.S. Phase III study evaluating the role of GAMMAGARD. The study design is undergoing review with the U.S. Food and Drug Administration with the intention of initiating patient recruitment later in 2008. The trial is expected to include approximately 35 leading academic centers in the United States that are members of ADCS.

About GAMMAGARD LIQUID

GAMMAGARD LIQUID

GAMMAGARD LIQUID is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective IgA deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction.

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose a
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 BellBrook Labs announced ... support for the powerful Orthogonal Pooled Screening (OPS) ... Center at the Lankenau Institute for Medical Research ... to measurably improve successful drug discovery outcomes using ... rare, drug-like libraries available nowhere else, coupled to ...
(Date:4/16/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... on Thursday, April 30, 2015 at 4:00 PM Eastern ... a conference call at 4:30 PM Eastern Time to ... for the future. , The conference call will be ... and in the Investor Relations section of Cytokinetics’ website ...
(Date:4/16/2015)... Regis Technologies looks forward to being part ... (AACR) annual meeting. Regis will exhibit at this year's ... 18, in Philadelphia and running through April 22, 2015. ... oldest and largest organization focused on cancer research. It ... with survivors to promote awareness and research funding. ...
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
Breaking Biology Technology:BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4
... FindTheBest,s Private Cord Blood Bank comparison is a ... their newborn,s cord blood. Cord blood storage ... for families with children in need of certain therapeutic treatments. ... informed decision when deciding on a cord blood bank. ...
... (NASDAQ: MASI ) today announced that its management is ... Conference at The New York Palace in New York on Tuesday, ... of the presentation will be available on the Masimo website at ... following the live presentation. About Masimo Masimo ...
... Nov. 14, 2011 Virobay, Inc., ... portfolio of cysteine protease inhibitors for the treatment ... cancer, presented data showing that one of the ... mouse model of bone cancer pain.  Virobay has ...
Cached Biology Technology:Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference 2Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 2Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 3
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... 2, 2015 At its 2015 ACMG Annual ... , the American College of Medical Genetics and ... to its Board.  Members of the ACMG Board of ... forming and advancing its policies and programs. ACMG is ... "It,s an eventful time in medical genetics and ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... has achieved a major breakthrough in fishing sustainability on coral ... collapse. "Fishermen and scientists have long wondered how many ... says Dr Nick Graham of the ARC Centre of Excellence ... "The consequences of overfishing can be severe to the ...
... leading cause of blindness worldwide. Although it can be treated, ... protect themselves. According to a new study by Lawson Health ... not screened until the disease has reached moderate or advanced ... sight." It slowly and irreversibly destroys the optic nerve ...
... University of Oklahoma ecology and evolutionary biology graduate student ... Achieve Results Fellowship. Carla Atkinson, a doctoral student in ... College of Arts and Sciences Department of Zoology, was ... research into freshwater mussels in North America and their ...
Cached Biology News:World-first discovery 'can help save coral reefs' 2World-first discovery 'can help save coral reefs' 3Lawson research shows Canadians don't believe their eyes 2
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse monoclonal [ICRF 44] to Integrin alpha M...
Biology Products: